GSK 2849330

Drug Profile

GSK 2849330

Alternative Names: Anti-HER3-monoclonal-antibody; GSK-2849330

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Sep 2017 GlaxoSmithKline completes a phase I trial for Solid tumours (Late-stage disease) in Australia, USA and Netherlands (IV) (NCT01966445)
  • 01 Jun 2016 GlaxoSmithKline completes a phase I PET study for Solid tumours (Late-stage disease) in the Netherlands (NCT02345174)
  • 06 May 2016 Pharmacodynamics data from a preclinical study presented at the at 107th Annual Meeting of the American Association for Cancer Research(AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top